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Medulloblastoma is one of the most frequent among pediatric brain tumors, and
it has been classified in various subgroups. Some of them already benefit from
quite good therapeutic options, whereas others urgently need novel therapeutic
approaches. Epigenetic modulators have long been studied in various types of cancer.
Within this review, we summarize the main preclinical studies regarding epigenetic
targets (such as HDAC, SIRT, BET, EZH2, G9a, LSD1, and DNMT) inhibitors in
medulloblastoma. Furthermore, we shed light on the increasing number of applications
of drug combinations as well as hybrid compounds involving epigenetic mechanisms.
Nevertheless, in the studies published so far, mainly un-specific or old modulators have
been used, and the PKs (brain permeability) have not been well-evaluated. Thus, these
findings should be considered as a starting point for further improvement and not as a
final result.
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INTRODUCTION
Medulloblastoma (MB) is one of the most frequent and extensively studied pediatric brain tumors.
According to the WHO-classification of central nervous system tumors, four main genetically
defined subgroups have been described: WNT, SHH, group 3, and group 4. Each of these groups
has its unique expression signature and clinical outcome (1–4). Guerreiro Stucklin et al. recently
well-summarized the differences in biological and clinical behavior between subgroups (3). Because
of the heterogeneity of the various groups of MB, a targeted and efficient therapy, specifically for
young patients, is very challenging (2). Epigenetic modulators have long been studied in various
types of cancers, and some of them have been approved mainly for the treatment of hematological
malignancies (5). These compounds are a particularly appealing therapy approach because they do
not alter irreversibly the genetic code but act on reversible epigenetic marks, with a lower risk of
side effects. In MB, a malignant brain tumor, the main challenge relies on the fact that whatever
small molecule used as a therapeutic agent has to be able to cross the blood-brain barrier (6).
The molecular epigenetic deregulation in MB has been recently reviewed, shedding light onto the
pathways involved in the disease, on their biological importance as well as on the possible targets
to hit (7, 8).
In this review we would like to highlight the latest preclinical and clinical efforts regarding the
application of epigenetic modulators inMB. An overview of the presented compounds, their targets
and effects in MB can be found in Table 1.
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SINGLE EPIGENETIC MODULATORS IN
MEDULLOBLASTOMA
Histone (De)acetylation Modifiers/Readers
HDAC Inhibitors (HDACi)
HDACi are among the oldest and deeply studied class of
epigenetic modulators. In time, the most widely studied HDACi
have not been isoform selective, but they were targeting
more than one HDAC, specially class I and/or IIa/b HDACs.
Nevertheless, selective isoform-specific modulators are more and
more developed (9). Vorinostat, romidepsin, and belinostat are
FDA-approved drugs to treat rare T-cell lymphomas by re-
expressing silenced tumor suppressor genes. Currently, many
preclinical studies are evaluating the effects of these inhibitors
on MB (8). Surprisingly, relatively few clinical studies have been
conducted with these validated inhibitors in MB, and most of
them are closed or finished (10).
Older studies described valproic acid (VPA) as a potential
treatment in various MB cell lines (11, 12), nevertheless this
compound seems no longer under evaluation as newer studies
cannot be found. Parthenolide, an HDAC1i, has been shown to
be active in DAOY and D283med MB cancer stem cells, which
aberrantly overexpress HDAC1 (13). In the same study also
other HDACi, such as vorinostat, entinostat, or romidepsin, were
tested resulting less active. However, the authors of this study
noticed that very low concentrations of the HDACi resulted in
an increase, rather than a decrease, in proliferative activity (13).
Recently, another well-known pan-HDACi, panobinostat, was
reported to suppress leptomeningeal seeding, a rare complication
in MB spreading, causing brain and spinal cord inflammation in
a mouse model (14).
Milde et al. developed a Group 3MB HD-MB03 cell line
and xenograft model with high HDAC expression levels and
sensitivity to HDACi, such as vorinostat and panobinostat (15).
A meaningful example of the involvement of HDACi in the
SHH signaling pathway has been given by Canettieri et al. They
showed that the HDAC1/2 selective inhibitors HDiA and HDiB
blocked GLI1 and GLI2 activity through their acetylation, and
SHH MB cell growth in several SHH MB cell lines (16). Despite
these interesting results, no follow up studies have been published
so far.
The natural compound curcumin, through HDAC inhibition
and HDAC4 level depletion, reduced tumor growth and
significantly increased survival in the Smo/Smo transgenic MB
mouse model displaying HDAC4 overexpression. However, due
to the pleiotropism displayed by curcumin, these positive results
might not only be ascribed to HDAC4 inhibition but also to other
off-target effects (17).
In 2015, Ecker et al. used the class IIa-selective HDACi
MAZ1863 and MAZ1866 in Group 3MB cancer cells and
compared them to vorinostat (pan-HDACi) and to the class I
specific inhibitor MS-275 (entinostat). MAZ1863 and MAZ1866
had only very weak effects on MYC-MB cells, whereas vorinostat
and entinostat efficiently reduced the metabolic activity in MYC-
MB cells. These results give precious hints on the development
of novel therapies with selective HDACi in MYC- dependent
MB (10).
Interestingly, when tested in the MED8A MB cell line, the
novel non-toxic HDAC6/8/10 inhibitor TH34modestly impaired
colony growth and specifically induced caspase-dependent
programmed cell death in a dose-dependent manner (18). TH34
warrants deeper evaluation and could be an interesting candidate
for in vivo studies.
To sum up, the well-established and approved HDACi have
so far failed to demonstrate a significant antitumoral effect in
solid malignancies in preclinical and clinical settings (19), in
contrast to leukemias and lymphomas. The failure of translating
preclinical results into clinical success has been extensively
discussed (20). Most likely, insufficient pharmacological study
design regarding the clinical situation such as compound
concentrations and their pharmacokinetic as well as dynamic
properties are the primarily suspected factors (21).
SIRT Inhibitors
Sirtuins (SIRTs), also known as class III HDACs, are NAD+
dependent deacetylases considered as a separate family of
enzymes including seven different isoforms (hSIRT1-7). So far,
there is very little literature evidence about the use of SIRT
modulators in MB (22). In 2013, Ma et al. demonstrated that
SIRT1 was overexpressed in human MB cells. In their work, they
showed that lowered SIRT1 expression levels by siRNA or SIRT1
pharmacological inhibition with nicotinamide resulted in growth
arrest and apoptosis in MB cells (23).
In contrast, Tiberi and coworkers found that the
downregulation of the BLC6/BCOR/SIRT1 complex, a potent
repressor of the SHH pathway, led to MB growth in human
cells and in a mouse model. They demonstrated that SIRT1 is
necessary for the BCL6 function (24), thus SIRT1 inhibition
might be a double-edged sword in MB treatment. Therefore,
researchers should proceed with caution for SIRT1 modulation
in MB. The different results reported by these research groups
well-summarize the problem of the context-dependent function
of epigenetic targets (in this case SIRT1) in different experimental
settings and MB subgroups.
BET Inhibitors (BETi)
The BET (Bromodomain and Extra-Terminal domain) proteins
BRD2, BRD3, and BRD4, have been extensively studied in brain
tumors including MB (25). These proteins are epigenetic readers
as they recognize acetyl-lysine residues and acetylated chromatin,
which usually mark active enhancers, thus they are important
mediators of gene activation. High levels of H3K27Ac mark
super-enhancers regulate key genes in cancer growth, and are
sensitive to BET inhibition (26).
The BETi JQ-1 is one of the most studied in the
literature. Tang et al. demonstrated that reduced expression
of BRD4 via RNAi or its pharmacologic inhibition by JQ-
1 resulted in decreased proliferation and tumor growth in
SHH MB, reducing the expression of the glioma-associated
oncogenes GLI1 and GLI2 (27). The same compound also
led to positive results in Group 3MB, as MYC-driven
MBs are sensitive to BETi. Henssen et al. described JQ-
1 to be active in a human Group 3MB xenograft model
via MYC downregulation, as it reduced tumor volume and
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TABLE 1 | Summary of the epigenetic modulators and combinations active in MB.
Compound Structure Target Results Combination
Suberoylanilide-
hydroxamic acid,
vorinostat
HDACs Active in DAOY and
D283med MB cancer stem
cells (13)
Active in HD-MB03 cell line
and xenograft model (15)
Efficiently reduced the
metabolic activity in
MYC-MB cells (10).
Synergistic effect in D283med
cells, but not in DAOY with
decitabine (41). Newer study for
both cell lines (13).
Synergistic effects of VPA and
vorinostat with irradiation in MB
(42).
The aurora kinase inhibitor
MLN8237 had additive inhibition
effects on MB group 3 cell lines
(43)
Romidepsin HDAC1/2 Active in DAOY and
D283med MB cancer stem
cells (13)
–
Panobinostat HDACs Suppressed leptomenigeal
seeing in a MB mouse
model (14)
Active in HD-MB03 cell line
and xenograft model (15)
–
Valproic acid, VPA Class I/IIa
HDACs
Potential treatment in
various MB cell lines (11, 12)
Synergistic effects of VPA and
vorinostat with irradiation in MB
(42)
Parthenolide HDAC1 Active in DAOY and
D283med MB cancer stem
cells (13)
–
MS-275,
entinostat
Class I
HDACs
Active in DAOY and
D283med MB cancer stem
cells (13)
Efficiently reduced the
metabolic activity in
MYC-MB cells. (10)
–
HDiA HDAC1/2 Block GLI1/2 activities and
SHH MB growth (16)
–
(Continued)
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TABLE 1 | Continued
Compound Structure Target Results Combination
HDiB HDAC1/2 Block GLI1/2 activities and
SHH MB growth (16)
–
Curcurmin HDACs Increased survival in the
Smo/Smo transgenic MB
mouse model (17)
–
MAZ1863 Class IIa
HDACs
Only very weak effects on
MYC-MB cells (10)
–
MAZ1866 Class IIa
HDACs
Only very weak effects on
MYC-MB cells (10)
–
TH34 HDAC 6/8/10 Induced
caspase-dependent
programmed cell death in
various MB cell lines (18)
–
Nicotinamide SIRTs SIRT1 inhibition might be a
double edge sword in MB
treatment (24)
–
JQ-1 BETs Decreased proliferation and
tumor growth in SHH MB
via reducing the expression
of. GLI1 and GLI2 (27)
Active in a human group
3MB xenograft model via
MYC downregulation
(28–30)
Effective combination with the
CDK inhibitor milciclib, as both
regulate the MYC function in MB
via different actions, prolonging
survival in a MB animal model
(32)
I-BET151 BETs Inhibition of the SHH
pathway in SHH-MB cells
as well as in a MB mouse
model (31)
–
(Continued)
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TABLE 1 | Continued
Compound Structure Target Results Combination
Decitabine DNMTs Found to be quite inactive in
DAOY (13, 38) and
UW228MB cells (38) as
well, differently D283med
cells were quite sensitive
(13)
Synergistic effect in D283med
cells, but not in DAOY with
decitabine (41). Newer study for
both cell lines (13).
Triple combination of
decitabine/irradiation and
abacavir turned out to work
effectively in various MB cell lines
(41)
Phenylbutyrate in combination
with decitabine and the tyrosine
kinase inhibitor Gleevec induced
apoptosis in DAOY and UW228
3MB cell lines (38).
Zebularine DNMTs Inhibits the expression of
SHH pathway components,
such as SMO and GLI1, in
DAOY and ONS-76MB (39)
DNMTi zebularine has been
tested in combination with
vincristine in SHH MB cells,
displaying a synergistic effect
(39)
MC2840
(compound 2)
DNMTs Impaired MB-SC growth led
to high MB-SC
differentiation rates (40)
–
MC3343
(compound 5)
DNMTs Significantly impaired the
MB-SC growth rate (40)
–
3-
Deazaneplanocin
A, DZNep
EZH2 Indirect and rather
unspecific EZH2i in MB (33)
–
MC3629 EZH2 Reduces in a MB
xenografted mice the tumor
volume, stemness and cell
proliferation and lastly
induces apoptosis (34)
–
(Continued)
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TABLE 1 | Continued
Compound Structure Target Results Combination
UNC0638 G9a Reduces DAOY proliferation
via controlling the USP37
expression mediated by
G9a (35)
–
SP2509 LSD1 Disruptor of the
CoREST–LSD1 complex
active in various MB cell
lines (36)
–
4SC-202 HDAC1/2/3
and LSD1
– Active in various MB cell lines
(36)
Sodium
Phenylbutyrate
HDACs – Phenylbutyrate in combination
with decitabine and the tyrosine
kinase inhibitor imatinib induced
apoptosis in DAOY and UW228
3MB cell lines (38)
NL-103 HDAC/HH – NL-103 is a dual inhibitor of the
HDACs and HH pathway with
potential activity in MB (44)
prolonged survival rates (28). Similar results, corroborating
the potential of JQ-1 in downregulating MYC expression,
have been obtained by two other independent research groups
(29, 30). Furthermore, JQ-1 has been demonstrated to block
stem cell-associated signaling and was able to induce cell
senescence in a MYC-MB cellular model as well as in xenograft
mice (30).
Another BETi, namely I-BET151, has been shown to provide
biological effects similar to JQ-1 in SHHMB. More precisely, this
compound reduced the BRD4 binding to the GLI1 gene locus,
thus resulting in the inhibition of the SHH pathway in SHH MB
cells as well as in a MB mouse model (31).
Currently, JQ-1 is not in clinical trials for MB treatment due
to its poor pharmacokinetic and pharmacodynamic properties
(32). It is quite surprising that other BETi similar to JQ-1, such
as RG6146 (TEN-010) or OTX105, which are currently evaluated
in clinical trials for other cancer types [ClinicalTrials.gov
NCT01987362, NCT02259114], have never been tested in MB
even in preclinical studies. Nevertheless, BETi represent a
promising strategy to follow the development of novel MB
therapies.
Histone (De)methylation Modifiers
EZH2 Inhibitors (EZH2i)
Enhancer of zeste homolog 2 (EZH2) is a histone lysine N-
methyltransferase involved in the PRC2 (Polycomb Repressive
Complex 2), which has been widely studied in cancer including
MB. One of the first published studies on MB used the
rather toxic DZNep, an inhibitor of S-adenosyl-L-homocysteine
hydrolase, as an indirect and quite unspecific EZH2i (33).
Recently, our research group published the pyrazole compound
MC3629 as a simplified analog of the two different SAM-
competitive EZH2i EPZ005687 and GSK2816126. This particular
compound was not only active in human SHH MB cancer cell
models, where it significantly impaired H3K27me3 and PCNA
protein levels leading to apoptosis, detected as an increased
level of cleaved caspase 3, but also, to our knowledge for
the first time, in a SHH MB murine model. Importantly,
MC3629 better penetrated the blood-brain barrier in vitro and
in vivo, when compared to the parent compound GSK2816126.
This might explain at least in part why MC3629, despite
its lower in vitro potency, efficiently reduced H3K27me3
levels in brain and cerebellum of MB xenografted mice
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leading to decreased tumor volume, reduced stemness and cell
proliferation ability, and, lastly, induction of apoptosis (34).
These encouraging results confirm the importance of EZH2
in MB.
G9a Inhibitors
The deubiquitylase USP37 was identified as a target of REST,
one of the main regulatory complexes in brain development and
neurogenesis with aberrant overexpression in MB (5). Dobson
et al. showed that the downregulated USP37 in human MB
could be re-expressed after G9a inhibition. In more details,
G9a catalyzes mono- and di-methylation of histone H3K9,
and its histone methyltransferase activity correlated with gene
repression of USP37 in MB. The USP37 promoter in MB
possesses a significant level of histone H3K9 trimethylation,
which was considerably diminished upon treatment of the DAOY
cells with the G9a inhibitor UNC0638. This has been the first
and unique pivotal study highlighting the importance of G9a
inhibition, leading to arrest of MB cell proliferation via control
of the USP37 expression (35). However, this is only the first
step toward a G9a-based MB treatment, as this target needs to
be further validated not only in other MB models but also in
opportune in vivo studies.
LSD1 Inhibitors (LSD1i)
Lysine-specific demethylase 1 (LSD1), also known as KDM1A,
has been the first of several protein lysine demethylases to be
discovered. The modulation of this enzyme has also been studied
in MB. Recently, it has been shown that SP2509 inhibited the
enzymatic activity of LSD1 rather than acting as a protein-
protein disruptor of the CoREST–LSD1 complex. SP2509 was
able to block the growth of various human MB cell lines (DAOY,
D283med, and ONS-76) through direct LSD1 inhibition (36).
This study has a pivotal role since it could be used as a starting
point for deeper mechanistic studies as well as for a novel
therapeutic approach in MB.
DNMT Inhibitors (DNMTi)
DNA methyltransferases (DNMTs) are a family of enzymes
that catalyze the transfer of a methyl group to the C5-cytosine
residue of DNA. Aberration of DNA methylation leads to a
wide variety of diseases, including cancer. DNMTi are one
of the most studied epigenetic modulators after HDACi in
cancer. The nucleoside analogs azacytidine and decitabine have
been approved by FDA mainly in hematological malignancies
(37). These compounds inhibit DNMTs after being incorporated
into the DNA, leading to reduced methylation levels often
resulting in enhanced tumor suppressor gene expression and
finally in increased apoptosis (37). Decitabine was found to
be quite inactive in DAOY (13, 38) and UW228MB cells
(38); differently, D283med cells seemed to be quite sensitive
to the treatment with this inhibitor (13). Another nucleoside
inhibitor, zebularine, inhibits the expression of SHH pathway
components, such as SMO and GLI1 in DAOY and ONS-
76MB cell lines, leading to inhibition of their proliferation
and to increase of apoptosis rates (39). The main problems of
these nucleoside analogs are their poor chemical stability and
high toxicity (37). Relatively few non-nucleoside inhibitors are
known to date. One of them, developed in our research group
has also been tested in MB. Compound 5 and compound 2,
both structural isomer of the SGI-1027, have been tested for
the first time as non-nucleoside inhibitors in mouse MB stem
cells (MB-SC), expressing high levels of DNMT1. Compound
5 arrested the cell clonogenic activity impairing MB-SC growth
rate, evaluated by quantification of PCNA levels, and induced
cell adhesion and differentiation, evaluated by βIII-tubulin. In
these assays, compound 5 displayed the highest growth arrest,
while compound 2 induced higher differentiation already after
treatment with lower doses (40). Both compounds are interesting
tools for further in vivo validation, but also a starting point for
further drug development.
COMBINATIONS CONTAINING AT LEAST
ONE EPIGENETIC MODULATOR AND
HYBRID COMPOUNDS
Chemoresistance is one of the key reasons why drug
combinations are applied in therapy. Targeting a disease by just
one active principle often results in drug resistance. This problem
might be overcome by using two different drugs that target two
different molecular pathways involved in the same disease.
In MB, this strategy has also been used to various epigenetic
modulators in combination with other molecules either targeting
epigenetic pathways or non-epigenetic ones. Furthermore, we
shed light on novel, innovative hybrid compounds targeting at
least one epigenetic molecule as following.
Combinations of Two (or More) Epigenetic
Modulators
Patties et al. published in a first study the effects of combination
of several epigenetic modulators, such as the DNMTi decitabine,
VPA and vorinostat as HDACi, in MB and later they extended
the previous study with the use of irradiation, a common physical
therapy approach to fight various cancers (41).
They discovered that the treatment of D283med cells with
vorinostat and decitabine produced a synergistic effect in
reducing tumor cell viability, whereas the exposure of DAOY
cells to the same compounds did not have a synergistic effect
(41). However, a more recent study by Yuan et al. resulted
in a synergistic effect in both cell lines (13). This example
shows that the precise assay conditions as well as concentrations
of the drugs, are crucial for the outcome of a study. The
last researchers also tested parthenolide in combination with
decitabine obtaining a synergistic effect (13). Despite the
numerous evidences of synergism by HDACi and DNMTi co-
treatment, the precise mechanism of their interplay still needs to
be elucidated (13, 41).
Interestingly, also the combination of VPA or vorinostat
with irradiation showed similar effects compared to
decitabine/irradiation treatments on the mentioned cell lines,
even though to a lower extent (42). The latter most powerful
combination deserves in vivo validation. Also, the combination
experiments without irradiation might provide a promising
Frontiers in Pediatrics | www.frontiersin.org 7 December 2018 | Volume 6 | Article 370
Zwergel et al. Epi-Drugs in Medulloblastoma
alternative therapeutic strategy, lowering the possibility of
resistance.
Combinations of Epigenetic and
Non-Epigenetic Modulators
Patties et al. did not only evaluate the combination of several
epigenetic modulators, but also combined them with abacavir,
a nucleoside analog HIV reverse transcriptase inhibitor, with
or without irradiation (41, 42). Abacavir is not only known
as an approved drug for HIV-treatment, but possesses also
potent anti-cancer effects due to its ability to inhibit the
telomerase activity, often overexpressed in several cancers
(41). The triple combination of decitabine, abacavir, and
irradiation turned out to work effectively in all three tested
cell lines (DAOY, MEB-Med8a, D283med), warranting
further in vivo investigations (41). Vorinostat has also
been tested in association with the aurora kinase inhibitor
MLN8237, leading to proliferation arrest in Group 3MB cell
lines (43).
Marino et al. evaluated the pan-HDAC inhibitor
4-phenylbutyrate in combination with the DNMTi decitabine
and the tyrosine kinase inhibitor imatinib. The co-treatment
reduced global methylation and induced apoptosis in DAOY and
UW228 3MB cell lines (38).
The DNMTi zebularine has been tested in combination with
the well-known anti-cancer agent vincristine, able to interact
with microtubules and tubulin, in SHH MB cells, displaying
a synergistic effect (39). All the aforementioned studies are
combining approved drugs or compounds which have already
been extensively studied in the preclinical and clinical stage for
other malignancies.
However, also newer chemical entity combinations have been
tested in MB. As reported earlier, MYC is an important player in
Group 3 and Group 4MB. JQ-1 is influencing this pathway via
BET inhibition and has been combined with the CDK inhibitor
milciclib, because CDKs regulate events in MYC function as well.
This combination was well-tolerated, reduced tumor cell growth,
and significantly prolonged survival in MB animal model (32).
In the future, the combination between BETi and CDKi could
be further evaluated using in combination with milciclib, already
in clinical trials [NCT01011439, NCT01301391], a BETi more
drug-like than JQ-1.
However, for the treatment of MB all the aforementioned
combinations are still in their early stage and need to
be carefully evaluated before proceeding to the clinical
area.
Hybrid Compounds
Hybrid compounds are single chemical entities hitting more
than one target. Some of these innovative compounds have
been also tested in MB. Inui et al. evaluated the dual
HDAC1/2/3 and LSD1 inhibitor 4SC-202 in various MB cell
lines (DAOY, D283med, and ONS-76). This compound proved
to be active targeting both enzymes in the CoREST-HDAC-
LSD1 complex. This study is one of the first examples using
dual epigenetic inhibitors in MB (36). 4SC-202 deserves a
deeper study regarding its detailed mechanism of action as
well as further evaluation as a novel innovative therapy
weapon.
NL-103, a dual inhibitor of the HDACs and SHH pathway,
shows a hybrid structure merging those of vismodegib, a
smoothened receptor (SMO) inhibitor approved by FDA for
other solid cancers, and vorinostat, which is known to target
the SHH pathway by influencing the acetylation status of GLI1
and GLI2 (16). This innovative compound, with its unique dual-
targeted activities, was able to inhibit SHH signaling pathway
acting on two different targets, in the oncogene fibroblast
model cell line NIH-3T3, where it was more effective than
the treatment with single targeting compounds. Thus, in this
study such a hybrid was proposed as an attractive candidate
to be tested in HH-sensitive MB, however it remains still
elusive since no further studies have been published so
far (44).
CONCLUSIONS AND PERSPECTIVES
In this review, we have summarized and highlighted epigenetic
modulators as promising drug targets in MB. However, there
is still a long way to go: mainly not very specific, or older
modulators have been used and often the brain permeability
has not been well-evaluated. The molecular genetics and
detailed epigenetic modulation of the various MB subgroups
need to be further studied. As the MB subgroup is a key
factor in choosing the right treatment, the development of
personalized medicine with highly specific modulators could
be a key in improving the poor survival rates of some MB
subgroups. Therefore, research should not only focus on the
design of more specific and selective epigenetic modulators,
but also should study deeper the more biologically oriented
factors, such as the tumor molecular genetics, the functional
analysis of epigenetic factors and their potential modulation.
In both cases, epigenetic modulators can be useful not only as
tools to better understand the molecular mechanisms in MB,
but also as novel potential drugs for innovative personalized
treatments.
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